Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

1.310 -0.141 (-9.70%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,164
Open 1.330
Bid (Size) 1.290 (1)
Ask (Size) 1.410 (1)
Prev. Close 1.451
Today's Range 1.300 - 1.425
52wk Range 1.100 - 7.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
Via Benzinga

Performance

YTD
-34.50%
-34.50%
1 Month
-22.94%
-22.94%
3 Month
-43.78%
-43.78%
6 Month
-27.22%
-27.22%
1 Year
-35.47%
-35.47%

More News

Read More
Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma
Via Benzinga
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
From OKYO Pharma LTD
Via GlobeNewswire
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESSWIRE
Why ClearOne Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful
Via Benzinga
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
From OKYO Pharma LTD
Via GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
Via FinancialNewsMedia
Exposures COVID-19
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease
Via Benzinga
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via ACCESSWIRE
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via Benzinga
Notice of General Meeting and Publication of Circular
From OKYO Pharma LTD
Via GlobeNewswire
Notice of Intention to Delist From The London Stock Exchange
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Via News Direct
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Via TheNewswire.com
Exposures Product Safety
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Via Benzinga
OKYO Pharma Announces PDMR Dealing
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.